Neurodegeneration
Welcome to this years Neurodegeneration session. Opening Remarks by Drs. Vemuri and Nordberg.
8:30 - 9:25 am (US CT)/15:30- 16:25 pm (Sweden)
SESSION 1 - Chair: Dr. Agneta Nordberg
Amyloid-β and tau biomarkers and clinical phenotype in dementia with Lewy bodies
- Dr. Kejal Kantarci
Cerebrovascular and tau pathologies contribute to gray matter neurodegeneration in dementia with Lewy bodies.- Dr. Daniel Ferreira Padilla
Selecting software pipelines for change in flortaucipir SUVR.- Dr. Christopher Schwarz
Alzheimer’s disease continuum profiled by fluid and imaging biomarkers within the ATN framework- Dr. Marco Bucci
What could tau PET tell us about the course of Alzheimer’s disease?- Dr. Konstantinos Ioannou
Discussion - all speakers (30 minutes)
9:30 - 10:30 am (US CT)/ 16:30- 17:30 pm (Sweden)
SESSION 2 - Chair: Dr. Kejal Kantarci
Imaging biomarkers beyond Aβ and Tau 1,
- Dr. Amit Kumar
Reactive Astrocytes Imaged with 11C-Deuterium-L-Deprenyl PET in Alzheimer's Disease.- Ms. Malgorzata Michalowska
Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer’s pathophysiology- Dr. Vijay Ramanan
Mapping and understanding Tau pathology in FTD subtypes and AD using the tau PET tracer PI2620.- Ms. Mona-Lisa Malarte
Pattern of brain glucose metabolism in isolated rapid eye movement sleep behavior disorder (iRBD) and its association with dopamine transporter availability.- Dr. Patricia Diaz-Galvan
Neurodegeneration-based subtypes of Alzheimer's disease: a multimodal perspective from FDG-PET and MRI biomarkers.- Ms. Sophia Wheatley
Discussion - all speakers (30 minutes)
9:15 - 10:10 am (US CT)/16:15- 17:10 pm (Sweden)
SESSION 3 - Chair: Dr. Daniel Ferreira Padilla
Future use and implementation of AD blood biomarkers from a clinical and epidemiological perspective
- Dr. Michelle Mielke
Factors underlying discordance in amyloid PET vs CSF: Validation of a continuous model of biomarker discordance across cohorts and PET tracers.- Dr. Elena Rodriguez-Vieitez
Relationship between synaptic, axonal, tau and astrocytic biomarkers with brain imaging and cognition over the course of Alzheimer's disease.- Dr. Joana Pereira
Plasma neurofilament light predicts mortality in patients with stroke.- Dr. Tania Gendron
Perivascular fibroblasts activity precedes the onset of ALS neurodegeneration.- Dr. Sebastian Lewandowski
Discussion - all speakers (30 minutes)
10:15 - 11:15 am (US CT)/17:15- 18:15 pm (Sweden)
SESSION 4 - Chair: Dr. Melissa Murray
In vivo binding of THK5317 and comparability with postmortem 3H-THK5117, 3H-MK6240 autoradiography and AT8 immunostaining in a 4R tauopathy case.
- Dr. Laetitia Lemoine
Neurofibrillary tangle maturity characterization of four phosphorylated tau fluid biomarkers.- Dr. Christina Moloney
Multimodal assessment of heterogeneity in Alzheimer's disease continuum.- Dr. Rosaleena Mohanty
Correlates of Neuroimaging measures with Pathological Scales of Cerebrovascular Disease- Dr. Aivi Nguyen
In vivo model of the cholineric pathways in aging and Alzheimer's disease.- Mr. Milan Nemy
Mayo Test Drive: Reliability and construct validity of the Stricker Learning Span and Symbols Test on a self-administered web-based testing platform optimized for smartphone- Dr. Aimee Karstens
Discussion - all speakers (30 minutes)